We are live on ! Find out more
ENZ

Enzo Biochem, Inc.

Delisted

ENZ was delisted on the 17th of April, 2025.

116 hedge funds and large institutions have $313M invested in Enzo Biochem, Inc. in 2017 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 41 increasing their positions, 32 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

28% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 32

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

3% less capital invested

Capital invested by funds: $322M → $313M (-$9.28M)

3% less funds holding

Funds holding: 120116 (-4)

14% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 22

62% less call options, than puts

Call options by funds: $436K | Put options by funds: $1.16M

Holders
116
Holders Change
-4
Holders Change %
-3.33%
% of All Funds
2.89%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
19
Increased
41
Reduced
32
Closed
22
Calls
$436K
Puts
$1.16M
Net Calls
-$719K
Net Calls Change
-$1.43M
Name Holding Trade Value Shares
Change
Change in
Stake
AQR Capital Management
51
AQR Capital Management
Connecticut
$554K +$587K +52,868 New
ZIM
52
Zacks Investment Management
Illinois
$548K +$407K +36,629 +234%
Bank of America
53
Bank of America
North Carolina
$528K +$87.9K +7,918 +19%
RhumbLine Advisers
54
RhumbLine Advisers
Massachusetts
$521K +$5.83K +525 +1%
UBS Group
55
UBS Group
Switzerland
$504K +$14.7K +1,322 +3%
American Century Companies
56
American Century Companies
Missouri
$496K
Squarepoint
57
Squarepoint
New York
$482K +$384K +34,600 +304%
PPA
58
Parametric Portfolio Associates
Washington
$455K -$30.7K -2,765 -6%
AA
59
ALPS Advisors
Colorado
$448K +$475K +42,771 New
New York State Common Retirement Fund
60
New York State Common Retirement Fund
New York
$425K
CCIA
61
Campbell & Co Investment Adviser
Maryland
$397K +$49.1K +4,420 +13%
Manulife (Manufacturers Life Insurance)
62
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$345K -$16.9K -1,524 -4%
CS
63
Credit Suisse
Switzerland
$334K +$355K +31,942 New
SCA
64
Secor Capital Advisors
New York
$323K +$342K +30,844 New
MLICM
65
Metropolitan Life Insurance Company (MetLife)
New York
$319K -$15.1K -1,362 -4%
RJT
66
Raymond James Trust
Florida
$314K
KBC Group
67
KBC Group
Belgium
$296K
AIG
68
American International Group
New York
$289K +$22.9K +2,064 +8%
DCM
69
Dupont Capital Management
Delaware
$280K -$403K -36,306 -58%
SIM
70
Spark Investment Management
New York
$268K +$284K +25,600 New
JP Morgan Chase
71
JP Morgan Chase
New York
$263K +$274K +24,677 New
VOYA Investment Management
72
VOYA Investment Management
Georgia
$262K
Neuberger Berman Group
73
Neuberger Berman Group
New York
$250K
NFA
74
Nationwide Fund Advisors
Ohio
$241K
Group One Trading
75
Group One Trading
Illinois
$220K +$233K +20,998 New

ENZ Hedge Fund Activity: Q3 2017 in Review

116 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q3 2017, worth a combined $313M — down 2.9% from $322M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of ENZ and 19 opened new positions — a net loss of 3 holders — while 32 trimmed existing stakes and 41 added.

The largest buyer was TIAA CREF Investment Management, adding an estimated $2.24M. The largest seller was First Light Asset Management, cutting an estimated $1.97M.

  • 116 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q3 2017, down from 120 in Q2 2017.
  • Funds reported $313M of Enzo Biochem, Inc. stock for Q3 2017, down 2.9% quarter-over-quarter.
  • 19 funds opened new Enzo Biochem, Inc. positions in Q3 2017 and 22 closed out, a net change of -3 holders.
  • The largest Enzo Biochem, Inc. buyer in Q3 2017 was TIAA CREF Investment Management, an estimated $2.24M added.
  • The largest Enzo Biochem, Inc. seller in Q3 2017 was First Light Asset Management, an estimated $1.97M sold.

Based on aggregated 13F filings for Q3 2017.